Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovaBay Pharmaceuticals (NBY) EPS (Weighted Average and Diluted) (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with -$0.22 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 100.92% to -$0.22 in Q3 2025 year-over-year; TTM through Sep 2025 was $24.64, a 406.47% increase, with the full-year FY2020 number at -$0.31, up 35.42% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.22 for Q3 2025 at NovaBay Pharmaceuticals, up from -$0.41 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $23.85 in Q3 2024 to a low of -$29.95 in Q1 2024.